Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.
|Articles|March 2, 2002
Alefacept valuable against psoriatic arthritis
New Orleans - Results from a single-center pilot study indicatethat I.V. alefacept (Amevive), the human LFA3-IgG1 fusion protein, may safelyand effectively improve the skin and joint manifestations of psoriatic arthritis,researchers from the Academic Medical Center, University of Amsterdam, TheNetherlands, reported at the annual meeting of the American Academy of Dermatology.
Advertisement
Advertisement
Related to this article
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
4
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
5